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PTEN/MMAC1, a tumour suppressor gene located on chromosome 10q23.3, has been found to be deleted in several types of
human malignancies. As the chromosomal region 10q22-qter commonly is affected by losses in melanomas, we addressed this
gene as tumour suppressor candidate in melanomas. Investigating PTEN/MMAC1 expression at mRNA level by semi-
quantitative reverse transcription-polymerase chain reaction, we did not ﬁnd a statistically signiﬁcant down-regulation in
melanoma resection specimens in comparison to acquired melanocytic nevi from which melanomas quite often are known to
arise. Upon immunohistochemistry, PTEN/MMAC1 protein expression in melanomas was not lost. Sequencing the PTEN/
MMAC1 cDNAs in 26 melanoma resection specimens (21 primary melanomas, ﬁve metastases), we detected three point
mutations and two nucleotide deletions which did not represent genetic polymorphisms. With respect to the predicted
protein sequences, all three point mutations were silent whereas the two frame shifts at the extreme C-terminus resulted in a
loss of the putative PDZ-targeting consensus sequence. As loss of this motif possibly impairs localization and function of
PTEN/MMAC1 in the two corresponding primary tumours, alterations of this tumour suppressor protein may participate in
some melanomas.
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Melanomas are one of the most aggressive of the skin cancers and
have shown a dramatic increase in incidence over the past decades
(Rigel et al, 1996). The genetic principles that underly the develop-
ment and progression of these tumours are only beginning to
emerge. Genomic regions that exhibit losses of heterozygosity
(LOH) and therefore suggest the presence of tumour suppressor
genes in sporadic melanomas, have been identiﬁed, among others,
at chromosomes 6q22-27 (Albino et al, 1994) and 11q22-23
(Robertson et al, 1999). Moreover, LOHs at chromosome 10 occur
in 30–60% of both early- and advanced-stage tumours (Newton,
1994; Bastian et al, 1998) and are an indicator of a poor clinical
prognosis (Healy et al, 1998). Segmental deletions were cytogeneti-
cally localized to 10q (Richmond et al, 1986; Parmiter et al, 1988;
Isshiki et al, 1993; Indsto et al, 1998) and subsequently narrowed
by studies of LOH to 10q22-qter (Isshiki et al, 1993; Herbst et
al, 1994; Walker et al, 1995; Healy et al, 1996). This region is also
a common target of LOH in a wide spectrum of sporadic cancers,
including neoplasias of the prostate (Trybus et al, 1996), thyroid
(Nelen et al, 1996), kidney (Speicher et al, 1994), endometrium
(Nagase et al, 1996), and bone (Raskind et al, 1996). Investigating
kinetics of melanoma tumour formation in animals, transfer of
chromosome 10q distal to 10q23.1 into melanoma cells caused a
severe reduction in tumour growth (Robertson et al, 1999).
One notable gene at the chromosomal locus 10q23.3 is the
tumour suppressor gene ‘phosphate and tensin hommolog deleted
on chromosome ten’( PTEN; Li et al, 1997; Steck et al, 1997), also
known as ‘mutated in multiple advanced cancers’ (MMAC1).B y
dephosphorylating the phosphatidylinositol-3,4,5-triphosphate, this
tumour suppressor negatively controls the phosphoinositide-3-
kinase signalling pathway for regulation of cell proliferation and
cell survival (Bonneau and Longy, 2000). Deletions and mutations
of PTEN/MMAC1 have been reported in a wide variety of human
cancers, including tumours of the brain, the lung, the prostate and
the breast (Teng et al, 1997; Bonneau and Longy, 2000; di Cristo-
fano and Pandolﬁno, 2000), placing this gene among the most
commonly mutated genes in human cancer. In melanoma cell
lines, inactivating deletions or mutations of PTEN have been
reported in 29–43% (Guldberg et al, 1997; Tsao et al, 1998,
2000). We therefore looked for PTEN/MMAC1 alterations in mela-
noma resection specimens at mRNA and protein level by semi-
quantitative RT–PCR, sequencing of cDNA transcripts and immu-
nohistochemistry.
MATERIALS AND METHODS
Puriﬁcation of mRNA from melanoma and nevus resection
specimens
Tissue specimens of primary and metastatic melanomas and
acquired melanocytic nevi were frozen in liquid nitrogen immedi-
ately after resection. Tissues were microdissected to separate
tumour from normal tissues. From patients where the PTEN/
MMAC1 cDNAs were found to be altered in the melanomas, blood
mononuclear cells were puriﬁed by Lymphoprep (Nycomed Phar-
ma, Oslo, Norway) and investigated as non-neoplastic tissues. Total
RNA was isolated by anion exchange on resin columns (RNA mini
kit, QIAGEN, Valencia, CA, USA), concentrated and desalted by
isopropanol precipitation and dissolved in 30 ml TE (10 mM Tris
HCl pH 8.0, 1 mM EDTA). Contaminating DNA was digested by
DNAse (Promega, Madison, WI, USA), and high yields of full-
length, double-stranded cDNA were then synthesised using ‘switch-
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www.bjcancer.coming mechanism at 5' end of RNA template’ (SMART, Clontech,
Palo Alto, CA, USA) as previously described (Endege et al,
1999). Brieﬂy, cDNA ﬁrst strands were synthesized in 10 l solution
containing 3 ml RNA sample, 1 mM cDNA synthesis primer, 1 mM
SMART II oligonucleotide and 2 ml5 6 ﬁrst strand buffer (Clon-
tech), 200 units MMLV reverse transcriptase (Gibco,
Gaithersburgh, MD, USA), 1 ml dNTP mix (2 mM ﬁnal concentra-
tion each) and 2 mM DDT at 428C for 1 h. Multiple second cDNA
strands were then synthesized in 100 ml volume containing 10 ml
ﬁrst strand cDNA, 2 mM PCR primer, 2 ml Advantage cDNA
polmyerase mix and 10 ml1 0 6 PCR buffer (Clontech) and 1 ml
dNTP mix (2 mM ﬁnal concentration each). Cycle conditions were:
958C 1 min, followed by multiple cycles at 958C 5 s, 658C5s ,
688C 6 min. After 15, 18, 21 and 24 cycles, 5 ml aliquots of each
PCR tube were electrophoresed on a 1.2% agarose/ethidiumbromid
gel to determine the optimal number of PCR cycles with high
cDNA yields but not high-molecular-weight smear. Presence of
cDNA was then checked by PCR ampliﬁcation of b-actin in a ﬁnal
volume of 50 ml containing 2.5 units Taq DNA polymerase and
5 ml1 0 6 PCR buffer (Gibco), 0.5 ml of each primer
(100 pmol ml
71) and 3 ml MgCl2 1.5 mM. PCR conditions were:
958C 10 min, 30 cycles of 958C3 0 s ,5 5 8C3 0 s ,7 2 8C3 0 s ,
followed by 728C 10 min. Primer sequences were: SMART II oligo-
nucleotide 5'-AAg CAg Tgg TAA CAA CGC AgA gTA CgC ggg-3';
cDNA synthesis primer 5'-AAg CAg Tgg TAA CAA CgC AgA gTA
CT-3'; PCR primer 5'-AAg CAg Tgg TAA CAA CgC AgA gT-3'; b-
actin-509-for 5'-TgA Cgg ggT CAC CCA CAC TgT gCC CAT
CTA-3'; b-actin-1169-rev 5'-CTA gAA gCA TTT gCg gTg gAC
gAT ggA ggg-3' (human b-actin gene, accession number
emhum4:HSAC07 X00351, Ponte et al, 1984). All PCR and hybri-
dization steps were performed on a GeneAmp 2400 thermal cycler
(Perkin Elmer, Norwalk, CT, USA).
Semi-quantitative reverse transcription (RT)–PCR
To compare the expression of the PTEN/MMAC1 gene in melano-
mas with those in acquired melanocytic nevi, we performed semi-
quantitative RT–PCRs. PTEN/MMAC1 cDNAs were ampliﬁed
using the primers PTEN-1545-for and PTEN-2277-rev in a ﬁrst
and the primers PTEN-1731-for and PTEN-2277-rev in a semi-
nested PCR. One hundred ng of each cDNA sample were ampliﬁed
in 50 ml PCRs as described above using the conditions 948C 1 min
and 18 cycles of 948C3 0s ,6 0 8C3 0s ,7 2 8C 60 s in a ﬁrst, and 12–
24 cycles in the semi-nested reaction, followed by 728C 10 min.
Five ml aliquots of each reaction after 30 cycles were electrophor-
esed on 2% agarose/ethidiumbromide gels. The number of PCR
cycles to detect PTEN/MMAC1 cDNAs in melanomas was
compared with those in acquired melanocytic nevi. To ensure
the presence of comparable amounts of amplifyable cDNA in the
PCRs, a 661 base pairs b-actin fragment was ampliﬁed as house-
keeping gene in separate reactions. PCR conditions for b-actin
ampliﬁcation were: 958C 1 min, 26 cycles of 958C3 0 s ,5 5 8C
30 s, 728C 30 s, followed by 728C 10 min. Primer sequences were:
PTEN-1545-for 5'-Agg gAg TAA CTA TTC CCA gTC-3'; PTEN-
1731-for 5'-CgA Cgg gAA gAC Aag TTC AT-3', PTEN-2277-rev
5'-Tgg TgT TTT ATC CCT CTT gA-3' (PTEN cDNA sequence,
accession number U92436; Steck et al, 1997). Results of the
semi-quantitative RT–PCRs were statistically analysed by the
logrank test for time-to-event data (Mantel-Haenszel test, Mantel
and Haenszel, 1959) deﬁning the resulting two-sided P-values to
be statistically signiﬁcant for P50.05.
Ampliﬁcation and sequencing of PTEN/MMAC1 cDNAs
To screen for mutations and deletions in the coding region of
the PTEN/MMAC1 gene, we used unique primers and direct
sequencing of the PCR product as previously described (Liu
and Kagan, 1999). A 1475 bp DNA fragment was ﬁrst ampliﬁed
by PCR using the primers PP1u and PP1d (Wang et al, 2000). In
nested PCRs, 602 and 752 bp cDNA fragments were synthesised
using the primer pairs F1/R1 and F2/R2, respectively. Cycle
conditions were: 948C 1 min, 40 cycles of 948C9 0 s ,5 6 8C
120 s, 728C 150 s, followed by 728C 10 min in the ﬁrst PCR
and 948C 1 min, 40 cycles of 948C6 0 s ,5 0 8C 120 s, 728C
150 s, followed by 728C 10 min in the nested PCRs. In each case,
as a control for a successful RT of the RNA, we ampliﬁed a
661 bp b-actin cDNA fragment. Primer sequences were: PP1u
5'-AgA gCC ATT TCC ATC CCT gCA-3' (nucleotides 945–
964); PP1d 5'-gTg TCA AAA CCC TgT ggA Tg-3' (nucleotides
2420–2401; Wang et al, 2000); F1-for 5'-AgC TTC TgC CAT
CTC TCT CCT CC-3', R1-rev 5'-gAT TCT TTA ACA ggT AgC
TA-3', F2-for 5'-Agg gAg TAA CTA TTC CCA gTC-3' (identical
with PTEN-1525-for), R2-rev 5'-Tgg TgT TTT ATC CCT CTT
gA-3' (Liu and Kagan, 1999). The DNA bands were visualized
on 2% agarose/ethidiumbromide gels. PTEN/MMAC1 ampliﬁcons
were then puriﬁed and the QIAquick PCR puriﬁcation kit
according to the manufacturer’s instructions (QIAGEN) and
sequenced at a concentration of 50 ng ml
71 with a GeneAmp
PCR system 9600 using ABI Prism dGTP BigDye Terminator
Ready Reaction Kits and the AmpliTaq DNA polymerase FS
according to the manufacturer’s protocol (Perkin Elmer, Seqlab,
Go ¨ttingen, Germany). For sequencing PTEN/MMAC1 cDNA tran-
scripts from both sides, the primers F-1, R-1, F-2 and R-2 were
used. PCRs consisted of 25 cycles including a denaturation step
at 968C for 10 s, a primer annealing step at 508C for 5 s and
a chain elongation step at 608C for 60 s. Cycle sequencing
products were then ethanol precipitated, run on a 4% polyacry-
lamide 7 M urea gel and analysed with the ABI Prism 377
Genetic Analyzer (Perkin-Elmer; Seqlab). The resulting sequences
were aligned to known DNA sequences in the database of the
National Center for Biotechnology Information (NCBI, Bethesda,
MD, USA, http://www.ncbi.nlm.nih.gov/BLAST). PTEN/MMAC1
protein sequences predicted by the cDNA sequences were
compared with the PTEN/MMAC1 wild type protein sequence
using the BLASTX sofware at the NCBI.
Immunohistochemical staining of PTEN/MMAC1 protein
Serial 4 m-thin parafﬁn sections from formalin-ﬁxed and parafﬁn-
embedded melanoma and acquired melanocytic nevus tissues were
deparafﬁnised and rehydrated in graded ethanol solutions. After
retrieval pretreatment by 750 W microwave at 858C in 0.1 M
sodium citrate buffer pH 6.0 for 20 min, unspeciﬁc binding was
blocked by 10% goat serum (Vector, Wertheim-Bettingen,
Germany). Following overnight incubation at room temperature
with the primary antibodies, the sections were washed repeatedly
in destilled water and phosphate-buffered saline (PBS). Next, slides
were incubated with sheep-anti-mouse-antibody as secondary anti-
body (Amersham-Buchler, Braunschweig, Germany) and
developed using the streptavidin-biotin-peroxidase complex tech-
nique as described (Hsu et al, 1981). The visualisation was
performed with a nickel-enhanced diaminobenzidine (DAB) reac-
tion, resulting in a black staining of structures containing the
epitope (Hsu and Soban, 1982). Sections were counterstained with
hematoxylin and mounted with Eukitt
1 (Merck, Darmstadt,
Germany). The monoclonal antibodies NCL-PTEN (Novocastra,
Newcastle upon Tyne, UK, dilution 1:100), S100 (Linaris,
Wertheim, Germany, dilution 1:3), HMB45 (Loxo, Dossenheim,
Germany, prediluted) and CD68 (Dako, Hamburg, Germany, dilu-
tion 1:80) were used for the detection of the respective proteins.
As a negative control, the primary antibody was substituted by
equal amounts of normal mouse immunoglobulin G (Santa Cruz
Biotechnology, Santa Cruz, CA, USA, dilution 1:100) in parallel
experiments.
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PTEN/MMAC1 gene expression is not down-regulated in
melanomas in comparison to acquired melanocytic nevi
Semi-quantitative RT–PCRs were done with 19 acquired melano-
cytic nevus and 18 melanoma tissue specimens (seven nodular
melanomas, 10 superﬁcial spreading melanomas and 1 acrolentigi-
nous melanoma from the tumours listed in Table 1). The presence
of comparable amounts of amplifyable cDNA was ensured by
ampliﬁcation of b-actin as housekeeping gene. Using 100 ng of
each sample for 24 PCR cycles, 661 bp b-actin amplicons of
comparable amounts were observed on agarose gels (data not
shown). The possibility of ampliﬁcation of genomic DNA was
eliminated by b-actin PCRs without RT, which were negative in
all specimens (data not shown). Next, expression of the PTEN/
MMAC1 gene was evaluated by semi-quantitative PCR analysis.
Following 12 cycles of semi-nested PCR, a single acquired melano-
cytic nevus (5%) and a single melanoma (6%) were positive. After
14 cycles, ﬁve nevi (26%) and seven melanomas (39%) showed
positive result. The 344 bp ampliﬁcons were seen in seven nevi
(37%) and eight melanomas (44%) following 16 cycles, in 13 nevi
(68%) and 14 melanomas (78%) following 18 cycles, in 15 nevi
(79%) and 17 melanomas (94%) following 20 and 22 cycles.
Following 24 PCR cycles, four nevi and none of the melanomas
remained negative. Applying the logrank test for time-to-event data
(Mantel-Haenszel test), the resulting two-sided P-value of 0.17
indicated no statistically signiﬁcant difference of the semi-quantita-
tive RT–PCR testing nevi and melanoma tissue samples. We have
to remark that due to the relative low number of tested tissue
samples the log rank test has limited power to detect differences.
The estimated hazard ratio for melanomas versus nevi was 1.6
(95% conﬁdence interval 0.81; 3.23).
Mutations and deletions of PTEN/MMAC1 cDNAs were
found in some melanomas
Twenty-six melanoma resection specimens (seven nodular melano-
mas, 10 superﬁcial spreading melanomas, one acrolentiginous
melanoma, one polypoid melanoma, one melanoma not classiﬁed,
three cutaneous, three subcutaneous metastases, tumours listed in
Table 1) were succesfully used for RNA puriﬁcation and reverse
transcription. Following PCR ampliﬁcation and sequencing of
PTEN/MMAC1 cDNAs, sequences were compared with the known
PTEN/MMAC1 cDNA sequence (genbank accession number
emhum7:HSU93051; Steck et al, 1997) using the BLASTN software.
Three point mutations and two deletions were detected in ﬁve
melanomas whereas wild type of nucleotide sequence was found
in 21 samples (Table 1, Figure 1).
Next, the PTEN/MMAC1 protein sequences predicted by the
cDNA sequences that we found were compared with the known
PTEN/MMAC1 protein sequence (PTEN_HUMAN 000633 and
NM_000314, Li et al, 1997) using the BLASTX sofware. None of
the three detected point mutations resulted in changes of amino
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 1 Synopsis of the results of PTEN/MMAC1 cDNA sequences, predicted protein sequences and immunohistochemical staining of melanomas
Type of Breslow Clark’s Age Gender cDNA Predicted Staining of
melanoma (mm) level Localisation (years) (m. w) sequence protein protein
a Clinical outcome
SSM 0.6 IV leg 62 M wt WT ++ NED after 19 m
SSM 0.6 III head 82 M wt WT ++ NED after 22 m
SSM 1.5 IV abdomen 48 M wt WT ++ LN met after 26 m
SSM 1.4 IV leg 54 F wt WT +/++ NED after 55 m
SSM 1.0 IV back 71 M wt WT NS NED after 29 m
SSM 5.5 V foot 75 F 2233 del T N 401 ++ LN met after 11 m
SSM 8.5 IV arm 86 F wt WT +/++ NED after 4 m
SSM 2.8 IV arm 78 F wt WT +/++ no follow up
SSM 1.2 IV arm 73 M wt WT +/++ no follow up
SSM 0.7 IV back 59 M wt WT ++ no follow up
NM 1.3 IV head 50 M wt WT ++ no follow up
NM 13 V back 80 M wt WT ++ LN met after 1 m
NM 3.4 III leg 27 M wt WT ++ NED after 15 m
NM 5.2 V back 73 M wt WT NS NED after 10 m
NM 0.3 III back 44 M 1420 g?A WT ++ NED after 27 m
NM 1.4 III back 64 M 2214 del g N 393 +/++ NED after 10 m
NM 0.2 II back 36 M 1808 C?T WT +/++ NED after 4 m
MM 1.3 IV leg 35 F wt WT +/++ NED after 2 m
PM 9 V trunk 45 M wt WT ++ no follow up
ALM
b 5 V foot 79 M wt WT NS simultan. cut. met.
cut. met.
c leg 75 F wt WT +/++ NED after 23 m
cut. met.
b head 79 M wt WT NS no follow up
cut. met.
d leg 66 M 1547 C?T WT ++ no follow up
s.c. met.
e arm 38 M wt WT ++ bone met.
h
s.c. met.
f leg 64 F wt WT +/++ cut. met. after 13 m
s.c .met.
g leg 67 F wt WT +/++ cut. met. after 13 m
A=adenine; Breslow=tumour thickness according to Breslow; C=cytosine; cut. met.=cutaneous metastasation; del=deletion; F=female; g=guanine; LN=lymph node; m=months;
M=male; MM=melanoma not classiﬁed; NED=no evidence of disease; NM=nodular melanoma; N 393=nonsense protein sequence beginning at amino acid 393; NS=no
successful immunohistochemical staining in repeated experiments; PM=polypoid melanoma; s.c.met.=subcutaneous metastasation; simultan.=simultaneous; SSM=superﬁcial
spreading melanoma; T=thymine; wt=wild type of PTEN/MMAC1 cDNA sequence (according to NCBI accession number U92436); WT=wild type of PTEN/MMAC1 protein
sequence (in comparison to NCBI accession number O08586); 1420 g?A=exchange of guanine by adenine at nucleotide 1420.
aUpon immunohistochemistry, staining of
endothelial cells was considered as internal positive control and rated as ++.
bALM and cutaneous metastases were diagnosed simultaneously.
cPrimary melanoma occurred
19 years before, histology of primary tumour is unknown.
dThe primary melanoma at the foot was not further classiﬁed, tumour thickness according to Breslow 2.7 mm, Clark’s
level IV.
ePrimary melanoma is unknown.
fPrimary melanoma at the leg occurred 53 months ago, tumour thickness according to Breslow 4.3 mm, Clark’s level V.
gLentigo maligna
melanoma at the leg occurred 24 years ago, tumour thickness according to Breslow not known, Clark’s level III.
hBone metastases developed 2 months before excision of the
subcutaneous metastasis.
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tions as they did not alter the predicted protein sequence. The two
deletions that we found resulted in frame shifts of the nucleotide
sequence followed by subsequent nonsense protein sequence at
the C-terminus of the PTEN/MMAC1 protein without protein
truncation. As a consequence, the corresponding PTEN/MMAC1
proteins are predicted to have lost the normal ﬁve C-terminal
amino acids, which are supposed to function as PDZ-binding
consensus sequence (Leslie et al, 2000). Further critical motifs of
the PTEN/MMAC1 protein, e.g. the catalytic domain (tyrosin
phosphatase domain, Steck et al (1997); Ali et al (1999); genbank
accession number O08586, PTEN/MMAC1 exon 5, amino acids
122–132) or the phosphate acceptor sites (residues 233–240,
308–315) were altered in none of the 26 predicted PTEN/MMAC1
proteins.
The presence of genetic polymorphisms was excluded by sequen-
cing the PTEN/MMAC1 cDNAs from corresponding blood
mononuclear cells, which were regarded as non-neoplastic tissues
of the patients where PTEN/MMAC1 cDNAs were found to be
altered in the melanoma.
In the clinical follow up, 19 of the 26 patients were seen in
regular intervals. Progression of the disease was observed in
seven patients with three cutaneous, three lymph node and one
bone metastases (Table 1). Looking at the ﬁve patients with
cDNA alterations, one patient with a deletion in the PTEN/
MMAC1 cDNA suffered from lymph node metastasis 11 months
after primary surgery. In respect to statistical correlation of
PTEN/MMAC1 cDNA alterations with the clinical course of the
disease, the number of investigated melanoma samples was too
small.
Immunohistochemical detection of the PTEN protein in
melanomas and acquired melanocytic nevi
Expression of the PTEN/MMAC1 protein was analysed in six
acquired melanocytic nevi, 18 primary and ﬁve metastatic melano-
mas. Melanoma tissues corresponded to the samples investigated
for PTEN/MMAC1 gene expression and cDNA sequence. Evaluat-
ing the tissue sections of the nevi, distinct nuclear staining was
seen in the majority of melanocytes which was comparable to
the signals in endothelial cells with respect to intensity (data not
shown). Immunoreactions were also positive in cells of the hair
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Wild type Wild type
Nodular melanoma, Clark III Nodular melanoma, Clark II
TGC  AGCAATTCACTGTAAAGCTGGAAAGGAAC GAACTGGTGTAATGATAT GTGCATAT GTGGT  GATA  TCAAAGTAGAGTTCTTTCACAAACACAACAAGATGC TA
GTGGTGATATCAAAGTA GAGTTCTTCCACAAACAGAACAAGATGCTA TG CAGCAATTCACTGTAAAGCTGGAAAGGGACGAACTGGTGTAATGATATGTG CATAT
Figure 1 Part of the PTEN/MMAC1 cDNA sequences in melanomas in comparison to the wild type sequences. Guanine was found to be exchanged by
adenine at nucleotide 1420 in a nodular melanoma, Clark’s level III (left). Cytosine was found to be exchanged by thymine at nucleotide 1808 in a nodular
melanoma Clark’s level II (right).
A C
B D
Figure 2 Immunhistochemical staining of serial tissue sections of a nod-
ular melanoma, tumour thickness according to Breslow 1.4 mm, Clark’s
level IV. The PTEN/MMAC1 protein was detected in melanoma cells
and was not restricted to tumour associated macrophages. (a) Hematoxylin
Eosin, (b) HMB45, (c) CD68, (d) PTEN/MMAC1 staining (all magniﬁcation
256, nickel enhanced DAB reaction resulting in black signals).
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mis.
Nineteen of the 23 melanoma sections had accompanying vascu-
lar endothelial cells present, which showed strong PTEN/MMAC1
immunostaining in the nuclei, were graded ++, and served as
internal positive control as described previously (Zhou et al,
2000). In these 19 melanomas, the PTEN/MMAC1 protein was
detected in the melanoma cells and was not restricted to tumour
associated macrophages (Table 1, Figure 2). In most cases, the
intensity of signals in the melanoma cells was comparable to that
in endothelial cells and signals were located in the nuclei. In 10
melanomas, nuclear staining intensity varied from weak (+) to
moderate (++) nuclear PTEN/MMAC1 immunostaining. In the
remaining four of the 23 investigated melanoma tissues, immuno-
histochemical staining was not successful as endothelial cells
remained negative as well.
PTEN/MMAC1 immunohistochemistry was also positive for
those two primary melanomas which harboured a nucleotide dele-
tion in the PTEN/MMAC1 cDNA sequence. As these deletions at
cDNA level resulted in predicted nonsense sequences of the protein
at the C-terminus, the PTEN/MMAC1 protein might further be
detected by the monoclonal NCL-PTEN antibody which has been
produced by immunisation with the 200 amino acids at the C
terminus.
DISCUSSION
PTEN/MMAC1 is one of the most commonly mutated genes in
human cancer (Teng et al, 1997; Bonneau and Longy, 2000; di
Cristofano and Pandolﬁno, 2000). As this tumour suppressor gene
is located at chromosome 10q23.3 and melanomas frequently
harbour deletions at chromosome 10q22-qter (Isshiki et al, 1993;
Herbst et al, 1994; Walker et al, 1995; Healy et al, 1996, 1998) like
carcinomas of the prostate (Trybus et al, 1996) and the kidney
(Speicher et al, 1994), inactivation of PTEN/MMAC1 has been
supposed to occur in melanomas. Actually, deletions and muta-
tions of PTEN/MMAC1 have been found in 29–43% of
investigated melanoma cell lines (Guldberg et al, 1997; Tsao et
al, 1998; 2000). We therefore tested melanoma primary resection
specimens for mRNA and protein expression and PTEN/MMAC1
cDNAs for the presence of mutations or deletions.
Applying semi-quantitative RT–PCR, we could not ﬁnd a statis-
tically signiﬁcant down-regulation of the PTEN/MMAC1 expression
in melanomas at mRNA level in comparison to acquired melano-
cytic nevi, from which melanomas are known to arise. Likewise,
PTEN/MMAC1 expression was not lost at protein level as we
observed distinct nuclear signals in melanoma cells by immunohis-
tochemistry. Our immunohistochemical data contrast to the report
of Zhou et al (2000) who described absent or weak expression of
PTEN/MMAC1 nuclear signals in four primary and 30 metastatic
melanomas and assumed epigenetic PTEN/MMAC1 silencing.
Applying the same immunohistochemical protocols, the use of
different primary antibodies may cause these divergent results.
We used the monoclonal antibody NCL-PTEN which is commer-
cially available while Zhou et al (2000) and coworkers developed
their own PTEN/MMAC1-speciﬁc antibody 6H2.1.
Alterations of the PTEN/MMAC1 cDNA sequence were detected
in ﬁve of 26 investigated melanoma resection specimens, among
them three silent point mutations. The two deletions that we iden-
tiﬁed are predicted to result in nonsense protein sequences at the
extreme C-terminus of the PTEN/MMAC1 protein. Considering
the last three amino acids as consensus sequence for binding
PDZ domain containing proteins (Leslie et al, 2000), localisation
and function of PTEN/MMAC1 are possibly altered in the corre-
sponding two melanoma primary tumours. As PDZ domains are
known to recruit components of lipid signalling pathways to parti-
cular membranes (Montell, 1998; Nemoto and de Camilli, 1999),
deletion of the PDZ domain may disrupt targeting of the PTENM-
MAC1 protein to the plasma membrane (Leslie et al, 2000).
Refering to the function of PTEN/MMAC1 missing the putative
PDZ-targeting sequence, a PTEN/MMAC1 enzyme with a deletion
of the C-terminal ﬁve amino acids (Q399STOP mutation) has been
reported to retain full phosphatase activity but to be impaired in
inhibiting cell spreading and platelet derived growth factor
(PDGF)-induced membrane rufﬂing (Leslie et al, 2000; 2001) as
well as in inhibiting colony formation (Morimoto et al, 1999).
Similar to our ﬁndings, C-terminal frame shifts and missense
mutations of PTEN/MMAC1 have previously been identiﬁed in
glioblastomas (Ali et al, 1999; Bonneau and Longy, 2000).
The frequency of somatic mutations and deletions of PTEN/
MMAC1 in melanoma resection specimens is controversially
discussed so far: Microsatellite analyses demonstrated LOH at the
PTEN/MMAC1 locus in none of 23 primary cutaneous and 17
metastatic melanomas (0%; Bo ¨ni et al, 1998), in a single of 10
investigated melanomas (10%; Steck et al, 1997), in two of 44
informative primary and metastatic melanomas (4%; Herbst et
al, 1999) and in three of eight primary and in 18 of 31 metastatic
melanomas (3 and 58%, respectively; Birck et al, 2000). Applying
denaturing gel electrophoresis, none of three primary melanomas
with LOH but four of 61 melanoma metastases harboured muta-
tions of the PTEN/MMAC1 gene (Birck et al, 2000).
Reifenberger et al (2000) reported PTEN/MMAC1 mutations in
four of 37 investigated metastases (11%) from which two had lost
one PTEN/MMAC1 allele. Melanoma metastases seem to be
affected by LOH at the PTEN/MMAC1 locus more frequently as
was further reported for 33% of 21 cases; 19% of these specimens
harboured mutations in the remaining allele (Celebi et al, 2000). In
addition, Poetsch et al (2001) detected nine intronic mutations in
25 primary and 25 metastatic melanoma resection specimens
among them two mutations in metastases resulted in amino acid
changes. If these genetic alterations are the cause or the result of
metastazation, remains unclear. Mutations of PTEN/MMAC1 in
cell lines may be acquired during cell culture at least in some cases
as was demonstrated for six melanoma cell lines where none of the
mutations found in the cell lines have been recovered in the mela-
noma resection specimens from which the cell lines had been
derived from (Guldberg et al, 1997).
Altogether, involvement of the PTEN/MMAC1 tumour suppres-
sor gene in melanomas remains controversial. Our data do not
reveal a statistically signiﬁcant down-regulation of the PTEN/
MMAC1 expression at mRNA or protein level. Among 26 melano-
ma resection specimens, we here describe three silent point
mutations and two frame shifts of the PTEN/MMAC1 cDNA
sequence. The N-terminal phosphatase domain or the phosphate
acceptor sites were not affected by any mutation or deletion. The
two frame shifts at the extreme C-terminus were harboured by
melanoma primary tumours and resulted in a predicted loss of
the putative PDZ-targeting consensus sequence probably important
in localisation and function of the PTEN/MMAC1 protein. We
here ﬁrst report on single melanoma primary tumours that exhibit
PTEN/MMAC1 proteins predicted to lack the C-terminal PDZ-
binding motif, possibly impairing localization and function of this
tumour suppressor protein.
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